nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—ABCB1—peripheral nervous system neoplasm	0.301	1	CbGaD
Temsirolimus—CYP3A7-CYP3A51P—Tretinoin—peripheral nervous system neoplasm	0.0576	0.132	CbGbCtD
Temsirolimus—CYP3A7—Tretinoin—peripheral nervous system neoplasm	0.0576	0.132	CbGbCtD
Temsirolimus—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0432	0.0987	CbGbCtD
Temsirolimus—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0303	0.0691	CbGbCtD
Temsirolimus—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0303	0.0691	CbGbCtD
Temsirolimus—CYP3A7—Vincristine—peripheral nervous system neoplasm	0.0265	0.0604	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Vincristine—peripheral nervous system neoplasm	0.0265	0.0604	CbGbCtD
Temsirolimus—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.021	0.0479	CbGbCtD
Temsirolimus—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.0199	0.0453	CbGbCtD
Temsirolimus—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.0182	0.0415	CbGbCtD
Temsirolimus—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0181	0.0414	CbGbCtD
Temsirolimus—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0169	0.0385	CbGbCtD
Temsirolimus—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0129	0.0295	CbGbCtD
Temsirolimus—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0121	0.0275	CbGbCtD
Temsirolimus—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0118	0.027	CbGbCtD
Temsirolimus—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00808	0.0184	CbGbCtD
Temsirolimus—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00774	0.0177	CbGbCtD
Temsirolimus—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00761	0.0174	CbGbCtD
Temsirolimus—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00709	0.0162	CbGbCtD
Temsirolimus—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00484	0.011	CbGbCtD
Temsirolimus—Sirolimus—ABCB1—peripheral nervous system neoplasm	0.000573	0.5	CrCbGaD
Temsirolimus—Tacrolimus—ABCB1—peripheral nervous system neoplasm	0.000573	0.5	CrCbGaD
Temsirolimus—Pain—Vincristine—peripheral nervous system neoplasm	0.000105	0.000473	CcSEcCtD
Temsirolimus—Constipation—Vincristine—peripheral nervous system neoplasm	0.000105	0.000473	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000473	CcSEcCtD
Temsirolimus—Rash—Melphalan—peripheral nervous system neoplasm	0.000104	0.000472	CcSEcCtD
Temsirolimus—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000104	0.000471	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000104	0.00047	CcSEcCtD
Temsirolimus—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000469	CcSEcCtD
Temsirolimus—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000103	0.000468	CcSEcCtD
Temsirolimus—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000103	0.000466	CcSEcCtD
Temsirolimus—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000465	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000103	0.000464	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000102	0.00046	CcSEcCtD
Temsirolimus—Face oedema—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000457	CcSEcCtD
Temsirolimus—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000101	0.000456	CcSEcCtD
Temsirolimus—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.0001	0.000454	CcSEcCtD
Temsirolimus—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.0001	0.000454	CcSEcCtD
Temsirolimus—Nausea—Topotecan—peripheral nervous system neoplasm	0.0001	0.000454	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.0001	0.000453	CcSEcCtD
Temsirolimus—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.0001	0.000452	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	9.96e-05	0.000451	CcSEcCtD
Temsirolimus—Nausea—Tretinoin—peripheral nervous system neoplasm	9.94e-05	0.00045	CcSEcCtD
Temsirolimus—Nausea—Isotretinoin—peripheral nervous system neoplasm	9.94e-05	0.00045	CcSEcCtD
Temsirolimus—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	9.9e-05	0.000448	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	9.85e-05	0.000446	CcSEcCtD
Temsirolimus—Infection—Etoposide—peripheral nervous system neoplasm	9.84e-05	0.000445	CcSEcCtD
Temsirolimus—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	9.83e-05	0.000445	CcSEcCtD
Temsirolimus—Asthenia—Dactinomycin—peripheral nervous system neoplasm	9.82e-05	0.000444	CcSEcCtD
Temsirolimus—Nausea—Melphalan—peripheral nervous system neoplasm	9.82e-05	0.000444	CcSEcCtD
Temsirolimus—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	9.79e-05	0.000443	CcSEcCtD
Temsirolimus—Influenza—Epirubicin—peripheral nervous system neoplasm	9.76e-05	0.000442	CcSEcCtD
Temsirolimus—Dysphagia—Epirubicin—peripheral nervous system neoplasm	9.76e-05	0.000442	CcSEcCtD
Temsirolimus—Dehydration—Doxorubicin—peripheral nervous system neoplasm	9.72e-05	0.00044	CcSEcCtD
Temsirolimus—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	9.7e-05	0.000439	CcSEcCtD
Temsirolimus—Body temperature increased—Vincristine—peripheral nervous system neoplasm	9.66e-05	0.000437	CcSEcCtD
Temsirolimus—Abdominal pain—Vincristine—peripheral nervous system neoplasm	9.66e-05	0.000437	CcSEcCtD
Temsirolimus—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	9.64e-05	0.000436	CcSEcCtD
Temsirolimus—Skin disorder—Etoposide—peripheral nervous system neoplasm	9.62e-05	0.000435	CcSEcCtD
Temsirolimus—Dry skin—Doxorubicin—peripheral nervous system neoplasm	9.58e-05	0.000434	CcSEcCtD
Temsirolimus—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	9.51e-05	0.000431	CcSEcCtD
Temsirolimus—Anorexia—Etoposide—peripheral nervous system neoplasm	9.44e-05	0.000427	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	9.41e-05	0.000426	CcSEcCtD
Temsirolimus—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	9.4e-05	0.000425	CcSEcCtD
Temsirolimus—Bronchitis—Epirubicin—peripheral nervous system neoplasm	9.39e-05	0.000425	CcSEcCtD
Temsirolimus—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	9.36e-05	0.000424	CcSEcCtD
Temsirolimus—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	9.35e-05	0.000423	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	9.33e-05	0.000422	CcSEcCtD
Temsirolimus—Gastritis—Doxorubicin—peripheral nervous system neoplasm	9.25e-05	0.000419	CcSEcCtD
Temsirolimus—Pain—Cisplatin—peripheral nervous system neoplasm	9.24e-05	0.000418	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	9.22e-05	0.000417	CcSEcCtD
Temsirolimus—Dysuria—Epirubicin—peripheral nervous system neoplasm	9.13e-05	0.000413	CcSEcCtD
Temsirolimus—Neutropenia—Epirubicin—peripheral nervous system neoplasm	9.13e-05	0.000413	CcSEcCtD
Temsirolimus—Asthenia—Alitretinoin—peripheral nervous system neoplasm	9.1e-05	0.000412	CcSEcCtD
Temsirolimus—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	9.09e-05	0.000412	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	9.07e-05	0.000411	CcSEcCtD
Temsirolimus—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	9.03e-05	0.000409	CcSEcCtD
Temsirolimus—Influenza—Doxorubicin—peripheral nervous system neoplasm	9.03e-05	0.000409	CcSEcCtD
Temsirolimus—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	9.02e-05	0.000408	CcSEcCtD
Temsirolimus—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	9.01e-05	0.000408	CcSEcCtD
Temsirolimus—Pruritus—Alitretinoin—peripheral nervous system neoplasm	8.98e-05	0.000406	CcSEcCtD
Temsirolimus—Weight decreased—Epirubicin—peripheral nervous system neoplasm	8.83e-05	0.0004	CcSEcCtD
Temsirolimus—Dyspnoea—Etoposide—peripheral nervous system neoplasm	8.83e-05	0.0004	CcSEcCtD
Temsirolimus—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	8.81e-05	0.000399	CcSEcCtD
Temsirolimus—Somnolence—Etoposide—peripheral nervous system neoplasm	8.8e-05	0.000399	CcSEcCtD
Temsirolimus—Asthenia—Vincristine—peripheral nervous system neoplasm	8.77e-05	0.000397	CcSEcCtD
Temsirolimus—Pneumonia—Epirubicin—peripheral nervous system neoplasm	8.76e-05	0.000396	CcSEcCtD
Temsirolimus—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	8.7e-05	0.000394	CcSEcCtD
Temsirolimus—Infestation—Epirubicin—peripheral nervous system neoplasm	8.7e-05	0.000394	CcSEcCtD
Temsirolimus—Vomiting—Dactinomycin—peripheral nervous system neoplasm	8.7e-05	0.000394	CcSEcCtD
Temsirolimus—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	8.69e-05	0.000393	CcSEcCtD
Temsirolimus—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	8.68e-05	0.000393	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	8.63e-05	0.000391	CcSEcCtD
Temsirolimus—Rash—Dactinomycin—peripheral nervous system neoplasm	8.63e-05	0.000391	CcSEcCtD
Temsirolimus—Decreased appetite—Etoposide—peripheral nervous system neoplasm	8.61e-05	0.00039	CcSEcCtD
Temsirolimus—Renal failure—Epirubicin—peripheral nervous system neoplasm	8.56e-05	0.000387	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	8.55e-05	0.000387	CcSEcCtD
Temsirolimus—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	8.55e-05	0.000387	CcSEcCtD
Temsirolimus—Fatigue—Etoposide—peripheral nervous system neoplasm	8.54e-05	0.000386	CcSEcCtD
Temsirolimus—Stomatitis—Epirubicin—peripheral nervous system neoplasm	8.48e-05	0.000384	CcSEcCtD
Temsirolimus—Constipation—Etoposide—peripheral nervous system neoplasm	8.47e-05	0.000383	CcSEcCtD
Temsirolimus—Pain—Etoposide—peripheral nervous system neoplasm	8.47e-05	0.000383	CcSEcCtD
Temsirolimus—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	8.46e-05	0.000383	CcSEcCtD
Temsirolimus—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	8.46e-05	0.000383	CcSEcCtD
Temsirolimus—Dysuria—Doxorubicin—peripheral nervous system neoplasm	8.45e-05	0.000382	CcSEcCtD
Temsirolimus—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	8.45e-05	0.000382	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	8.4e-05	0.00038	CcSEcCtD
Temsirolimus—Dizziness—Alitretinoin—peripheral nervous system neoplasm	8.39e-05	0.00038	CcSEcCtD
Temsirolimus—Diarrhoea—Vincristine—peripheral nervous system neoplasm	8.37e-05	0.000379	CcSEcCtD
Temsirolimus—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	8.34e-05	0.000378	CcSEcCtD
Temsirolimus—Haematuria—Epirubicin—peripheral nervous system neoplasm	8.3e-05	0.000376	CcSEcCtD
Temsirolimus—Epistaxis—Epirubicin—peripheral nervous system neoplasm	8.21e-05	0.000372	CcSEcCtD
Temsirolimus—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	8.17e-05	0.00037	CcSEcCtD
Temsirolimus—Sinusitis—Epirubicin—peripheral nervous system neoplasm	8.17e-05	0.00037	CcSEcCtD
Temsirolimus—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	8.15e-05	0.000369	CcSEcCtD
Temsirolimus—Nausea—Dactinomycin—peripheral nervous system neoplasm	8.13e-05	0.000368	CcSEcCtD
Temsirolimus—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	8.1e-05	0.000367	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	8.1e-05	0.000367	CcSEcCtD
Temsirolimus—Dizziness—Vincristine—peripheral nervous system neoplasm	8.08e-05	0.000366	CcSEcCtD
Temsirolimus—Vomiting—Alitretinoin—peripheral nervous system neoplasm	8.07e-05	0.000365	CcSEcCtD
Temsirolimus—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	8.05e-05	0.000365	CcSEcCtD
Temsirolimus—Infestation—Doxorubicin—peripheral nervous system neoplasm	8.05e-05	0.000365	CcSEcCtD
Temsirolimus—Rash—Alitretinoin—peripheral nervous system neoplasm	8e-05	0.000362	CcSEcCtD
Temsirolimus—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	7.99e-05	0.000362	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	7.98e-05	0.000361	CcSEcCtD
Temsirolimus—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	7.96e-05	0.00036	CcSEcCtD
Temsirolimus—Headache—Alitretinoin—peripheral nervous system neoplasm	7.95e-05	0.00036	CcSEcCtD
Temsirolimus—Renal failure—Doxorubicin—peripheral nervous system neoplasm	7.92e-05	0.000358	CcSEcCtD
Temsirolimus—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	7.85e-05	0.000355	CcSEcCtD
Temsirolimus—Rhinitis—Epirubicin—peripheral nervous system neoplasm	7.83e-05	0.000355	CcSEcCtD
Temsirolimus—Body temperature increased—Etoposide—peripheral nervous system neoplasm	7.83e-05	0.000354	CcSEcCtD
Temsirolimus—Abdominal pain—Etoposide—peripheral nervous system neoplasm	7.83e-05	0.000354	CcSEcCtD
Temsirolimus—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	7.83e-05	0.000354	CcSEcCtD
Temsirolimus—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	7.83e-05	0.000354	CcSEcCtD
Temsirolimus—Vomiting—Vincristine—peripheral nervous system neoplasm	7.77e-05	0.000352	CcSEcCtD
Temsirolimus—Asthenia—Cisplatin—peripheral nervous system neoplasm	7.76e-05	0.000351	CcSEcCtD
Temsirolimus—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	7.76e-05	0.000351	CcSEcCtD
Temsirolimus—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	7.72e-05	0.000349	CcSEcCtD
Temsirolimus—Rash—Vincristine—peripheral nervous system neoplasm	7.71e-05	0.000349	CcSEcCtD
Temsirolimus—Dermatitis—Vincristine—peripheral nervous system neoplasm	7.7e-05	0.000349	CcSEcCtD
Temsirolimus—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	7.7e-05	0.000348	CcSEcCtD
Temsirolimus—Haematuria—Doxorubicin—peripheral nervous system neoplasm	7.68e-05	0.000348	CcSEcCtD
Temsirolimus—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	7.68e-05	0.000348	CcSEcCtD
Temsirolimus—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	7.66e-05	0.000347	CcSEcCtD
Temsirolimus—Headache—Vincristine—peripheral nervous system neoplasm	7.66e-05	0.000347	CcSEcCtD
Temsirolimus—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	7.6e-05	0.000344	CcSEcCtD
Temsirolimus—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	7.56e-05	0.000342	CcSEcCtD
Temsirolimus—Nausea—Alitretinoin—peripheral nervous system neoplasm	7.54e-05	0.000341	CcSEcCtD
Temsirolimus—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	7.4e-05	0.000335	CcSEcCtD
Temsirolimus—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	7.39e-05	0.000334	CcSEcCtD
Temsirolimus—Eye disorder—Epirubicin—peripheral nervous system neoplasm	7.3e-05	0.000331	CcSEcCtD
Temsirolimus—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	7.3e-05	0.00033	CcSEcCtD
Temsirolimus—Nausea—Vincristine—peripheral nervous system neoplasm	7.26e-05	0.000329	CcSEcCtD
Temsirolimus—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	7.25e-05	0.000328	CcSEcCtD
Temsirolimus—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	7.25e-05	0.000328	CcSEcCtD
Temsirolimus—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	7.18e-05	0.000325	CcSEcCtD
Temsirolimus—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	7.14e-05	0.000323	CcSEcCtD
Temsirolimus—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	7.12e-05	0.000322	CcSEcCtD
Temsirolimus—Asthenia—Etoposide—peripheral nervous system neoplasm	7.11e-05	0.000322	CcSEcCtD
Temsirolimus—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	7.11e-05	0.000322	CcSEcCtD
Temsirolimus—Angiopathy—Epirubicin—peripheral nervous system neoplasm	7.09e-05	0.000321	CcSEcCtD
Temsirolimus—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	7.09e-05	0.000321	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB2—ERBB2—peripheral nervous system neoplasm	7.06e-05	0.00184	CbGpPWpGaD
Temsirolimus—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	7.06e-05	0.000319	CcSEcCtD
Temsirolimus—MTOR—Signaling by Insulin receptor—NRAS—peripheral nervous system neoplasm	7.05e-05	0.00184	CbGpPWpGaD
Temsirolimus—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	7.04e-05	0.000319	CcSEcCtD
Temsirolimus—MTOR—DAP12 signaling—ERBB2—peripheral nervous system neoplasm	7.03e-05	0.00184	CbGpPWpGaD
Temsirolimus—Chills—Epirubicin—peripheral nervous system neoplasm	7.01e-05	0.000317	CcSEcCtD
Temsirolimus—Pruritus—Etoposide—peripheral nervous system neoplasm	7.01e-05	0.000317	CcSEcCtD
Temsirolimus—MTOR—Regulation of Telomerase—AKT1—peripheral nervous system neoplasm	6.98e-05	0.00182	CbGpPWpGaD
Temsirolimus—MTOR—Costimulation by the CD28 family—AKT1—peripheral nervous system neoplasm	6.98e-05	0.00182	CbGpPWpGaD
Temsirolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—peripheral nervous system neoplasm	6.95e-05	0.00181	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—peripheral nervous system neoplasm	6.93e-05	0.00181	CbGpPWpGaD
Temsirolimus—MTOR—AMPK Signaling—AKT1—peripheral nervous system neoplasm	6.9e-05	0.0018	CbGpPWpGaD
Temsirolimus—MTOR—SREBP signalling—AKT1—peripheral nervous system neoplasm	6.9e-05	0.0018	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—ENO2—peripheral nervous system neoplasm	6.9e-05	0.0018	CbGpPWpGaD
Temsirolimus—Vomiting—Cisplatin—peripheral nervous system neoplasm	6.87e-05	0.000311	CcSEcCtD
Temsirolimus—Mental disorder—Epirubicin—peripheral nervous system neoplasm	6.85e-05	0.00031	CcSEcCtD
Temsirolimus—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	6.84e-05	0.000309	CcSEcCtD
Temsirolimus—Rash—Cisplatin—peripheral nervous system neoplasm	6.82e-05	0.000309	CcSEcCtD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—CASP3—peripheral nervous system neoplasm	6.81e-05	0.00178	CbGpPWpGaD
Temsirolimus—Dermatitis—Cisplatin—peripheral nervous system neoplasm	6.81e-05	0.000308	CcSEcCtD
Temsirolimus—Erythema—Epirubicin—peripheral nervous system neoplasm	6.8e-05	0.000308	CcSEcCtD
Temsirolimus—Malnutrition—Epirubicin—peripheral nervous system neoplasm	6.8e-05	0.000308	CcSEcCtD
Temsirolimus—Diarrhoea—Etoposide—peripheral nervous system neoplasm	6.78e-05	0.000307	CcSEcCtD
Temsirolimus—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	6.76e-05	0.000306	CcSEcCtD
Temsirolimus—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	6.71e-05	0.000304	CcSEcCtD
Temsirolimus—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	6.66e-05	0.000302	CcSEcCtD
Temsirolimus—MTOR—Immune System—CD55—peripheral nervous system neoplasm	6.65e-05	0.00174	CbGpPWpGaD
Temsirolimus—MTOR—IRS-mediated signalling—HRAS—peripheral nervous system neoplasm	6.62e-05	0.00173	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—ERBB2—peripheral nervous system neoplasm	6.61e-05	0.00173	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB2—peripheral nervous system neoplasm	6.61e-05	0.00173	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—ERBB2—peripheral nervous system neoplasm	6.61e-05	0.00173	CbGpPWpGaD
Temsirolimus—Back pain—Epirubicin—peripheral nervous system neoplasm	6.58e-05	0.000298	CcSEcCtD
Temsirolimus—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	6.56e-05	0.000297	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—ERBB2—peripheral nervous system neoplasm	6.55e-05	0.00171	CbGpPWpGaD
Temsirolimus—Dizziness—Etoposide—peripheral nervous system neoplasm	6.55e-05	0.000296	CcSEcCtD
Temsirolimus—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	6.53e-05	0.000296	CcSEcCtD
Temsirolimus—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	6.52e-05	0.000295	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—ERBB2—peripheral nervous system neoplasm	6.49e-05	0.0017	CbGpPWpGaD
Temsirolimus—Chills—Doxorubicin—peripheral nervous system neoplasm	6.49e-05	0.000294	CcSEcCtD
Temsirolimus—MTOR—Signaling by PDGF—ERBB2—peripheral nervous system neoplasm	6.47e-05	0.00169	CbGpPWpGaD
Temsirolimus—MTOR—Leptin signaling pathway—AKT1—peripheral nervous system neoplasm	6.46e-05	0.00169	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	6.44e-05	0.00168	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events—HRAS—peripheral nervous system neoplasm	6.44e-05	0.00168	CbGpPWpGaD
Temsirolimus—Nausea—Cisplatin—peripheral nervous system neoplasm	6.42e-05	0.000291	CcSEcCtD
Temsirolimus—MTOR—Disease—GNS—peripheral nervous system neoplasm	6.4e-05	0.00167	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—peripheral nervous system neoplasm	6.38e-05	0.00167	CbGpPWpGaD
Temsirolimus—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	6.33e-05	0.000287	CcSEcCtD
Temsirolimus—Vomiting—Etoposide—peripheral nervous system neoplasm	6.3e-05	0.000285	CcSEcCtD
Temsirolimus—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	6.29e-05	0.000285	CcSEcCtD
Temsirolimus—Erythema—Doxorubicin—peripheral nervous system neoplasm	6.29e-05	0.000285	CcSEcCtD
Temsirolimus—Anaemia—Epirubicin—peripheral nervous system neoplasm	6.29e-05	0.000285	CcSEcCtD
Temsirolimus—CYP3A5—Metabolism—PPIP5K2—peripheral nervous system neoplasm	6.26e-05	0.00164	CbGpPWpGaD
Temsirolimus—Rash—Etoposide—peripheral nervous system neoplasm	6.24e-05	0.000283	CcSEcCtD
Temsirolimus—Dermatitis—Etoposide—peripheral nervous system neoplasm	6.24e-05	0.000282	CcSEcCtD
Temsirolimus—MTOR—Insulin receptor signalling cascade—HRAS—peripheral nervous system neoplasm	6.21e-05	0.00162	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—HRAS—peripheral nervous system neoplasm	6.21e-05	0.00162	CbGpPWpGaD
Temsirolimus—Headache—Etoposide—peripheral nervous system neoplasm	6.2e-05	0.000281	CcSEcCtD
Temsirolimus—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	6.16e-05	0.000279	CcSEcCtD
Temsirolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—peripheral nervous system neoplasm	6.13e-05	0.0016	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—ERBB2—peripheral nervous system neoplasm	6.12e-05	0.0016	CbGpPWpGaD
Temsirolimus—Leukopenia—Epirubicin—peripheral nervous system neoplasm	6.09e-05	0.000276	CcSEcCtD
Temsirolimus—Back pain—Doxorubicin—peripheral nervous system neoplasm	6.09e-05	0.000276	CcSEcCtD
Temsirolimus—FKBP1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	6.04e-05	0.00158	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—NRAS—peripheral nervous system neoplasm	6.03e-05	0.00158	CbGpPWpGaD
Temsirolimus—Cough—Epirubicin—peripheral nervous system neoplasm	5.94e-05	0.000269	CcSEcCtD
Temsirolimus—MTOR—CXCR4-mediated signaling events—AKT1—peripheral nervous system neoplasm	5.9e-05	0.00154	CbGpPWpGaD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AKT1—peripheral nervous system neoplasm	5.9e-05	0.00154	CbGpPWpGaD
Temsirolimus—Convulsion—Epirubicin—peripheral nervous system neoplasm	5.89e-05	0.000267	CcSEcCtD
Temsirolimus—Nausea—Etoposide—peripheral nervous system neoplasm	5.88e-05	0.000266	CcSEcCtD
Temsirolimus—Hypertension—Epirubicin—peripheral nervous system neoplasm	5.87e-05	0.000266	CcSEcCtD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—peripheral nervous system neoplasm	5.86e-05	0.00153	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.85e-05	0.00153	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—peripheral nervous system neoplasm	5.84e-05	0.00153	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	5.83e-05	0.00152	CbGpPWpGaD
Temsirolimus—Anaemia—Doxorubicin—peripheral nervous system neoplasm	5.82e-05	0.000263	CcSEcCtD
Temsirolimus—Arthralgia—Epirubicin—peripheral nervous system neoplasm	5.79e-05	0.000262	CcSEcCtD
Temsirolimus—Chest pain—Epirubicin—peripheral nervous system neoplasm	5.79e-05	0.000262	CcSEcCtD
Temsirolimus—Myalgia—Epirubicin—peripheral nervous system neoplasm	5.79e-05	0.000262	CcSEcCtD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—AKT1—peripheral nervous system neoplasm	5.79e-05	0.00151	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—NRAS—peripheral nervous system neoplasm	5.77e-05	0.00151	CbGpPWpGaD
Temsirolimus—Anxiety—Epirubicin—peripheral nervous system neoplasm	5.77e-05	0.000261	CcSEcCtD
Temsirolimus—MTOR—Innate Immune System—IFNB1—peripheral nervous system neoplasm	5.77e-05	0.00151	CbGpPWpGaD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	5.75e-05	0.00026	CcSEcCtD
Temsirolimus—MTOR—Signaling by NGF—PTPN11—peripheral nervous system neoplasm	5.7e-05	0.00149	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—NRAS—peripheral nervous system neoplasm	5.68e-05	0.00148	CbGpPWpGaD
Temsirolimus—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	5.64e-05	0.00147	CbGpPWpGaD
Temsirolimus—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	5.63e-05	0.000255	CcSEcCtD
Temsirolimus—MTOR—ErbB1 downstream signaling—HRAS—peripheral nervous system neoplasm	5.59e-05	0.00146	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—peripheral nervous system neoplasm	5.59e-05	0.00146	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.57e-05	0.00146	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—SLC2A1—peripheral nervous system neoplasm	5.56e-05	0.00145	CbGpPWpGaD
Temsirolimus—Oedema—Epirubicin—peripheral nervous system neoplasm	5.55e-05	0.000251	CcSEcCtD
Temsirolimus—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	5.55e-05	0.000251	CcSEcCtD
Temsirolimus—Infection—Epirubicin—peripheral nervous system neoplasm	5.52e-05	0.00025	CcSEcCtD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—peripheral nervous system neoplasm	5.5e-05	0.00144	CbGpPWpGaD
Temsirolimus—Cough—Doxorubicin—peripheral nervous system neoplasm	5.49e-05	0.000249	CcSEcCtD
Temsirolimus—Convulsion—Doxorubicin—peripheral nervous system neoplasm	5.45e-05	0.000247	CcSEcCtD
Temsirolimus—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	5.44e-05	0.000246	CcSEcCtD
Temsirolimus—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	5.44e-05	0.000246	CcSEcCtD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	5.44e-05	0.00142	CbGpPWpGaD
Temsirolimus—Hypertension—Doxorubicin—peripheral nervous system neoplasm	5.43e-05	0.000246	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—NRAS—peripheral nervous system neoplasm	5.43e-05	0.00142	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—NRAS—peripheral nervous system neoplasm	5.4e-05	0.00141	CbGpPWpGaD
Temsirolimus—Skin disorder—Epirubicin—peripheral nervous system neoplasm	5.39e-05	0.000244	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB2—NRAS—peripheral nervous system neoplasm	5.37e-05	0.0014	CbGpPWpGaD
Temsirolimus—Myalgia—Doxorubicin—peripheral nervous system neoplasm	5.36e-05	0.000243	CcSEcCtD
Temsirolimus—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	5.36e-05	0.000243	CcSEcCtD
Temsirolimus—Chest pain—Doxorubicin—peripheral nervous system neoplasm	5.36e-05	0.000243	CcSEcCtD
Temsirolimus—MTOR—DAP12 signaling—NRAS—peripheral nervous system neoplasm	5.35e-05	0.0014	CbGpPWpGaD
Temsirolimus—Anxiety—Doxorubicin—peripheral nervous system neoplasm	5.34e-05	0.000242	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	5.32e-05	0.000241	CcSEcCtD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—MYC—peripheral nervous system neoplasm	5.32e-05	0.00139	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	5.31e-05	0.00139	CbGpPWpGaD
Temsirolimus—Anorexia—Epirubicin—peripheral nervous system neoplasm	5.29e-05	0.00024	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—peripheral nervous system neoplasm	5.27e-05	0.00138	CbGpPWpGaD
Temsirolimus—MTOR—PI-3K cascade—AKT1—peripheral nervous system neoplasm	5.21e-05	0.00136	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—HRAS—peripheral nervous system neoplasm	5.2e-05	0.00136	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—HRAS—peripheral nervous system neoplasm	5.16e-05	0.00135	CbGpPWpGaD
Temsirolimus—Oedema—Doxorubicin—peripheral nervous system neoplasm	5.14e-05	0.000232	CcSEcCtD
Temsirolimus—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	5.14e-05	0.000232	CcSEcCtD
Temsirolimus—Infection—Doxorubicin—peripheral nervous system neoplasm	5.1e-05	0.000231	CcSEcCtD
Temsirolimus—MTOR—PI3K/AKT activation—AKT1—peripheral nervous system neoplasm	5.09e-05	0.00133	CbGpPWpGaD
Temsirolimus—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	5.06e-05	0.000229	CcSEcCtD
Temsirolimus—MTOR—GAB1 signalosome—AKT1—peripheral nervous system neoplasm	5.05e-05	0.00132	CbGpPWpGaD
Temsirolimus—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	5.04e-05	0.000228	CcSEcCtD
Temsirolimus—MTOR—Immune System—CD34—peripheral nervous system neoplasm	5.04e-05	0.00132	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—NRAS—peripheral nervous system neoplasm	5.03e-05	0.00131	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—NRAS—peripheral nervous system neoplasm	5.03e-05	0.00131	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—peripheral nervous system neoplasm	5.03e-05	0.00131	CbGpPWpGaD
Temsirolimus—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	5.03e-05	0.000228	CcSEcCtD
Temsirolimus—Insomnia—Epirubicin—peripheral nervous system neoplasm	5.02e-05	0.000227	CcSEcCtD
Temsirolimus—MTOR—Cellular responses to stress—CDKN2A—peripheral nervous system neoplasm	5.02e-05	0.00131	CbGpPWpGaD
Temsirolimus—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	4.99e-05	0.000226	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—NRAS—peripheral nervous system neoplasm	4.98e-05	0.0013	CbGpPWpGaD
Temsirolimus—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	4.95e-05	0.000224	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—NRAS—peripheral nervous system neoplasm	4.94e-05	0.00129	CbGpPWpGaD
Temsirolimus—Somnolence—Epirubicin—peripheral nervous system neoplasm	4.94e-05	0.000223	CcSEcCtD
Temsirolimus—MTOR—ErbB1 downstream signaling—AKT1—peripheral nervous system neoplasm	4.93e-05	0.00129	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—peripheral nervous system neoplasm	4.93e-05	0.00129	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	4.93e-05	0.00129	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—NRAS—peripheral nervous system neoplasm	4.92e-05	0.00128	CbGpPWpGaD
Temsirolimus—Anorexia—Doxorubicin—peripheral nervous system neoplasm	4.9e-05	0.000222	CcSEcCtD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	4.87e-05	0.00127	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—peripheral nervous system neoplasm	4.86e-05	0.00127	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PPP3R1—peripheral nervous system neoplasm	4.85e-05	0.00127	CbGpPWpGaD
Temsirolimus—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	4.83e-05	0.000218	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	4.79e-05	0.000217	CcSEcCtD
Temsirolimus—Fatigue—Epirubicin—peripheral nervous system neoplasm	4.79e-05	0.000217	CcSEcCtD
Temsirolimus—Pain—Epirubicin—peripheral nervous system neoplasm	4.75e-05	0.000215	CcSEcCtD
Temsirolimus—Constipation—Epirubicin—peripheral nervous system neoplasm	4.75e-05	0.000215	CcSEcCtD
Temsirolimus—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4.73e-05	0.00123	CbGpPWpGaD
Temsirolimus—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	4.68e-05	0.000212	CcSEcCtD
Temsirolimus—MTOR—B Cell Activation—NRAS—peripheral nervous system neoplasm	4.65e-05	0.00122	CbGpPWpGaD
Temsirolimus—Insomnia—Doxorubicin—peripheral nervous system neoplasm	4.65e-05	0.00021	CcSEcCtD
Temsirolimus—MTOR—Signaling by VEGF—AKT1—peripheral nervous system neoplasm	4.59e-05	0.0012	CbGpPWpGaD
Temsirolimus—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	4.58e-05	0.000207	CcSEcCtD
Temsirolimus—Somnolence—Doxorubicin—peripheral nervous system neoplasm	4.57e-05	0.000207	CcSEcCtD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	4.55e-05	0.00119	CbGpPWpGaD
Temsirolimus—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	4.54e-05	0.000205	CcSEcCtD
Temsirolimus—MTOR—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	4.5e-05	0.00118	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NTS—peripheral nervous system neoplasm	4.48e-05	0.00117	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PPP3R1—peripheral nervous system neoplasm	4.48e-05	0.00117	CbGpPWpGaD
Temsirolimus—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	4.47e-05	0.000202	CcSEcCtD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	4.45e-05	0.00116	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4.45e-05	0.00116	CbGpPWpGaD
Temsirolimus—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	4.43e-05	0.000201	CcSEcCtD
Temsirolimus—Fatigue—Doxorubicin—peripheral nervous system neoplasm	4.43e-05	0.0002	CcSEcCtD
Temsirolimus—MTOR—Signaling by SCF-KIT—HRAS—peripheral nervous system neoplasm	4.41e-05	0.00115	CbGpPWpGaD
Temsirolimus—Constipation—Doxorubicin—peripheral nervous system neoplasm	4.39e-05	0.000199	CcSEcCtD
Temsirolimus—Pain—Doxorubicin—peripheral nervous system neoplasm	4.39e-05	0.000199	CcSEcCtD
Temsirolimus—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	4.39e-05	0.000199	CcSEcCtD
Temsirolimus—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	4.39e-05	0.000199	CcSEcCtD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	4.37e-05	0.00114	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	4.34e-05	0.00113	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CD55—peripheral nervous system neoplasm	4.3e-05	0.00112	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—NCAM1—peripheral nervous system neoplasm	4.28e-05	0.00112	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GNS—peripheral nervous system neoplasm	4.23e-05	0.00111	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.23e-05	0.0011	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	4.22e-05	0.0011	CbGpPWpGaD
Temsirolimus—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	4.2e-05	0.00019	CcSEcCtD
Temsirolimus—FKBP1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.19e-05	0.00109	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	4.16e-05	0.00109	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	4.09e-05	0.000185	CcSEcCtD
Temsirolimus—MTOR—Signaling by NGF—CASP3—peripheral nervous system neoplasm	4.09e-05	0.00107	CbGpPWpGaD
Temsirolimus—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	4.06e-05	0.000184	CcSEcCtD
Temsirolimus—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	4.06e-05	0.000184	CcSEcCtD
Temsirolimus—CYP3A7—Metabolism—NME1—peripheral nervous system neoplasm	4.06e-05	0.00106	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—HRAS—peripheral nervous system neoplasm	3.99e-05	0.00104	CbGpPWpGaD
Temsirolimus—Asthenia—Epirubicin—peripheral nervous system neoplasm	3.98e-05	0.00018	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	3.97e-05	0.00104	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	3.95e-05	0.00103	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—peripheral nervous system neoplasm	3.95e-05	0.00103	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	3.93e-05	0.00103	CbGpPWpGaD
Temsirolimus—Pruritus—Epirubicin—peripheral nervous system neoplasm	3.93e-05	0.000178	CcSEcCtD
Temsirolimus—MTOR—DAP12 signaling—HRAS—peripheral nervous system neoplasm	3.91e-05	0.00102	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—COX2—peripheral nervous system neoplasm	3.9e-05	0.00102	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	3.9e-05	0.00102	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ENO2—peripheral nervous system neoplasm	3.88e-05	0.00101	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—peripheral nervous system neoplasm	3.85e-05	0.00101	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	3.83e-05	0.001	CbGpPWpGaD
Temsirolimus—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	3.8e-05	0.000172	CcSEcCtD
Temsirolimus—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	3.78e-05	0.000171	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	3.73e-05	0.000974	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	3.69e-05	0.000964	CbGpPWpGaD
Temsirolimus—Asthenia—Doxorubicin—peripheral nervous system neoplasm	3.69e-05	0.000167	CcSEcCtD
Temsirolimus—MTOR—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	3.68e-05	0.000961	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	3.68e-05	0.000961	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—HRAS—peripheral nervous system neoplasm	3.68e-05	0.000961	CbGpPWpGaD
Temsirolimus—Dizziness—Epirubicin—peripheral nervous system neoplasm	3.67e-05	0.000166	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	3.67e-05	0.000959	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	3.65e-05	0.000953	CbGpPWpGaD
Temsirolimus—Pruritus—Doxorubicin—peripheral nervous system neoplasm	3.63e-05	0.000164	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	3.61e-05	0.000944	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	3.6e-05	0.00094	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.58e-05	0.000935	CbGpPWpGaD
Temsirolimus—Vomiting—Epirubicin—peripheral nervous system neoplasm	3.53e-05	0.00016	CcSEcCtD
Temsirolimus—MTOR—Insulin Signaling—AKT1—peripheral nervous system neoplasm	3.52e-05	0.00092	CbGpPWpGaD
Temsirolimus—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	3.51e-05	0.000159	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	3.5e-05	0.000915	CbGpPWpGaD
Temsirolimus—Rash—Epirubicin—peripheral nervous system neoplasm	3.5e-05	0.000158	CcSEcCtD
Temsirolimus—Dermatitis—Epirubicin—peripheral nervous system neoplasm	3.5e-05	0.000158	CcSEcCtD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—peripheral nervous system neoplasm	3.49e-05	0.000911	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	3.49e-05	0.000911	CbGpPWpGaD
Temsirolimus—Headache—Epirubicin—peripheral nervous system neoplasm	3.48e-05	0.000157	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	3.47e-05	0.000906	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—AKT1—peripheral nervous system neoplasm	3.45e-05	0.000902	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—NRAS—peripheral nervous system neoplasm	3.43e-05	0.000895	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.41e-05	0.000891	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—HRAS—peripheral nervous system neoplasm	3.41e-05	0.000889	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	3.4e-05	0.000889	CbGpPWpGaD
Temsirolimus—Dizziness—Doxorubicin—peripheral nervous system neoplasm	3.4e-05	0.000154	CcSEcCtD
Temsirolimus—MTOR—Signaling Pathways—VIP—peripheral nervous system neoplasm	3.4e-05	0.000887	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IFNB1—peripheral nervous system neoplasm	3.36e-05	0.000878	CbGpPWpGaD
Temsirolimus—Nausea—Epirubicin—peripheral nervous system neoplasm	3.3e-05	0.000149	CcSEcCtD
Temsirolimus—Vomiting—Doxorubicin—peripheral nervous system neoplasm	3.27e-05	0.000148	CcSEcCtD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	3.26e-05	0.000851	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PTPN11—peripheral nervous system neoplasm	3.25e-05	0.000849	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—AKT1—peripheral nervous system neoplasm	3.25e-05	0.000849	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	3.25e-05	0.000849	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	3.25e-05	0.000849	CbGpPWpGaD
Temsirolimus—Rash—Doxorubicin—peripheral nervous system neoplasm	3.24e-05	0.000147	CcSEcCtD
Temsirolimus—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	3.24e-05	0.000146	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	3.22e-05	0.000841	CbGpPWpGaD
Temsirolimus—Headache—Doxorubicin—peripheral nervous system neoplasm	3.22e-05	0.000146	CcSEcCtD
Temsirolimus—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.19e-05	0.000834	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	3.19e-05	0.000834	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	3.18e-05	0.00083	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	3.13e-05	0.000819	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.13e-05	0.000818	CbGpPWpGaD
Temsirolimus—MTOR—Disease—SLC2A1—peripheral nervous system neoplasm	3.13e-05	0.000817	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	3.12e-05	0.000815	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTPN11—peripheral nervous system neoplasm	3.11e-05	0.000812	CbGpPWpGaD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	3.08e-05	0.000804	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GNS—peripheral nervous system neoplasm	3.06e-05	0.000799	CbGpPWpGaD
Temsirolimus—Nausea—Doxorubicin—peripheral nervous system neoplasm	3.05e-05	0.000138	CcSEcCtD
Temsirolimus—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.01e-05	0.000786	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—AKT1—peripheral nervous system neoplasm	3.01e-05	0.000785	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—NME1—peripheral nervous system neoplasm	2.93e-05	0.000766	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.91e-05	0.00076	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	2.88e-05	0.000752	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—COX2—peripheral nervous system neoplasm	2.82e-05	0.000737	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—peripheral nervous system neoplasm	2.79e-05	0.00073	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	2.68e-05	0.0007	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HGF—peripheral nervous system neoplasm	2.59e-05	0.000678	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—ERBB2—peripheral nervous system neoplasm	2.57e-05	0.000671	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ENO2—peripheral nervous system neoplasm	2.56e-05	0.00067	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—HRAS—peripheral nervous system neoplasm	2.51e-05	0.000655	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	2.47e-05	0.000644	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—ERBB2—peripheral nervous system neoplasm	2.46e-05	0.000642	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	2.43e-05	0.000635	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.41e-05	0.000629	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.35e-05	0.000615	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	2.31e-05	0.000603	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—AKT1—peripheral nervous system neoplasm	2.21e-05	0.000578	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	2.21e-05	0.000578	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.18e-05	0.000568	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	2.17e-05	0.000568	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—BCHE—peripheral nervous system neoplasm	2.17e-05	0.000566	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	2.13e-05	0.000556	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	2.08e-05	0.000545	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.07e-05	0.00054	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—TH—peripheral nervous system neoplasm	2.04e-05	0.000532	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.01e-05	0.000526	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	2.01e-05	0.000524	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.97e-05	0.000514	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—NRAS—peripheral nervous system neoplasm	1.95e-05	0.00051	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.94e-05	0.000506	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.92e-05	0.000501	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.9e-05	0.000496	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PTPN11—peripheral nervous system neoplasm	1.89e-05	0.000494	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	1.88e-05	0.00049	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NRAS—peripheral nervous system neoplasm	1.87e-05	0.000488	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ENO2—peripheral nervous system neoplasm	1.85e-05	0.000484	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.76e-05	0.00046	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTPN11—peripheral nervous system neoplasm	1.75e-05	0.000457	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MYC—peripheral nervous system neoplasm	1.74e-05	0.000455	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.72e-05	0.000449	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GNAS—peripheral nervous system neoplasm	1.66e-05	0.000434	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ABCB1—peripheral nervous system neoplasm	1.63e-05	0.000426	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	1.57e-05	0.000409	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.56e-05	0.000408	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.56e-05	0.000407	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ERBB2—peripheral nervous system neoplasm	1.5e-05	0.000391	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.49e-05	0.00039	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	1.47e-05	0.000384	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.43e-05	0.000373	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.42e-05	0.000371	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	1.4e-05	0.000365	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ERBB2—peripheral nervous system neoplasm	1.38e-05	0.000361	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.37e-05	0.000359	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HRAS—peripheral nervous system neoplasm	1.37e-05	0.000357	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.36e-05	0.000356	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	1.32e-05	0.000344	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.32e-05	0.000344	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	1.31e-05	0.000343	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.31e-05	0.000342	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.26e-05	0.00033	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.22e-05	0.00032	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.22e-05	0.000318	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.21e-05	0.000317	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—AKT1—peripheral nervous system neoplasm	1.21e-05	0.000315	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	1.2e-05	0.000314	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	1.18e-05	0.000309	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	1.18e-05	0.000308	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—NRAS—peripheral nervous system neoplasm	1.14e-05	0.000297	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.13e-05	0.000294	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	1.11e-05	0.000291	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	1.11e-05	0.00029	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.06e-05	0.000277	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NRAS—peripheral nervous system neoplasm	1.05e-05	0.000275	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	1.05e-05	0.000273	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	1e-05	0.000261	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MYC—peripheral nervous system neoplasm	9.79e-06	0.000256	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	9.67e-06	0.000253	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.57e-06	0.00025	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	9.07e-06	0.000237	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	8.78e-06	0.000229	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	8.61e-06	0.000225	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	8.54e-06	0.000223	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.45e-06	0.000221	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	8.38e-06	0.000219	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HRAS—peripheral nervous system neoplasm	8.33e-06	0.000218	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HRAS—peripheral nervous system neoplasm	7.69e-06	0.000201	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.36e-06	0.000192	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—AKT1—peripheral nervous system neoplasm	7.35e-06	0.000192	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	7.28e-06	0.00019	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.94e-06	0.000181	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.85e-06	0.000179	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	6.84e-06	0.000179	CbGpPWpGaD
Temsirolimus—MTOR—Disease—AKT1—peripheral nervous system neoplasm	6.79e-06	0.000177	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.63e-06	0.000147	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	5.59e-06	0.000146	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	5.48e-06	0.000143	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.38e-06	0.000141	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.75e-06	0.000124	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—AKT1—peripheral nervous system neoplasm	4.49e-06	0.000117	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	3.24e-06	8.47e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	2.45e-06	6.39e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	2.31e-06	6.02e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.51e-06	3.94e-05	CbGpPWpGaD
